[THE INVESTOR] Korean pharma company BioLeaders will list on the secondary bourse KOSDAQ on July 7.
Established in 1999, the company develops drugs for immune disorders and other incurable diseases.
CEOs of BioLeaders: Sung Moon-hee (left) and Kim Sang-suk
Prior to listing on the tech-heavy KOSDAQ, BioLeaders was traded on KONEX -- a securities exchange exlusively for small and medium enterprises and venture companies.
It will issue 1.2 million shares within the range of 11,000 won (US$9.5) to 15,000 won per share. The company expects to raise 13.2 billion won to 18 billion won.
By Ahn Sung-mi (
sahn@heraldcorp.com)
